Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer

Novartis Investigative Site, Taipei

Novartis Investigative Site, Candiolo

Novartis Investigative Site, Cuneo

Associates in Oncology/Hematology, P.C., Rockville

Fairfax Northern Virginia Hematology Oncology Fairfax NVH, Fairfax

Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke

Novartis Investigative Site, Lleida

Novartis Investigative Site, Cremona

Novartis Investigative Site, Madrid

Novartis Investigative Site, Toulouse

Florida Cancer Specialists Dept.of FloridaCancerSpec. (2), Fort Myers

Novartis Investigative Site, Negrar

Novartis Investigative Site, Parma

Novartis Investigative Site, Saint-Herblain Cédex

Kansas City Cancer Center KCCC (3), Overland Park

Novartis Investigative Site, Lyon

Texas Oncology, P.A. Austin, Dallas

Texas Oncology, P.A. Presbyterian Hospital, Dallas

Texas Oncology, P.A. Texas Oncology - Sammons, Dallas

Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler

Texas Oncology, P.A. Dept. of Texas Oncology, Bedford

Novartis Investigative Site, Napoli

Comprehensive Cancer Centers of Nevada, Henderson

UCLA/ University of California Los Angeles Div. of Hematology/Oncology, Los Angeles

Tower Cancer Research, Beverly Hills

Cancer Care Associates Medical Group Dept. of CCA, Redondo Beach

Comprehensive Blood and Cancer Center Dept CBCC (3), Bakersfield

Central Coast Medical Oncology Corporation, Santa Maria

Novartis Investigative Site, Villejuif

Northwest Cancer Specialists Northwest Office (2), Portland

UNC/ Lineberger Comprehensive Cancer Center Dept. of Linberger Cancer Ctr, Chapel Hill

Novartis Investigative Site, Edmonton

Novartis Investigative Site, Montreal

Novartis Investigative Site, Helsinki

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Glasgow

Novartis Investigative Site, London

Novartis Investigative Site, London